Avadel Pharmaceuticals Ownership | Who Owns Avadel Pharmaceuticals?
Avadel Pharmaceuticals Ownership Summary
Avadel Pharmaceuticals is owned by 1.11% institutional investors, 4.77% insiders, and 94.11% retail investors. Knoll capital management is the largest institutional shareholder, holding 0.65% of AVDL shares. Polar Capital Healthcare Opports Inc is the top mutual fund, with 3.75% of its assets in Avadel Pharmaceuticals shares.
AVDL Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Avadel Pharmaceuticals | 1.11% | 4.77% | 94.11% |
Sector | Healthcare Stocks | 88.01% | 8.90% | 3.09% |
Industry | Specialty & Generic Drug Manufacturers Stocks | 34.23% | 10.67% | 55.10% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Knoll capital management | 600.00K | 0.65% | $8.44M |
Schulhoff | 137.00K | 0.14% | $1.44M |
Advisorshares investments | - | - | - |
Gendell jeffrey l | - | - | - |
Renaissance | - | - | - |
Rtw investments, lp | - | - | - |
Bfsg | - | - | - |
Edge wealth management | - | - | - |
Point72 asset management | - | - | - |
Geode capital management | - | - | - |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Knoll capital management | 600.00K | 5.68% | $8.44M |
Schulhoff | 137.00K | 0.53% | $1.44M |
Advisorshares investments | - | - | - |
Gendell jeffrey l | - | - | - |
Renaissance | - | - | - |
Rtw investments, lp | - | - | - |
Bfsg | - | - | - |
Edge wealth management | - | - | - |
Point72 asset management | - | - | - |
Geode capital management | - | - | - |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Knoll capital management | 600.00K | 5.68% | - |
Huntington national bank | 1.00 | - | - |
Schulhoff | 137.00K | 0.53% | - |
Zurcher kantonalbank (zurich cantonalbank) | - | - | -19.00 |
Signaturefd | - | - | -22.00 |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Janus henderson group | - | - | -12.92M |
Rtw investments, lp | - | - | -8.80M |
Polar capital | - | - | -6.75M |
Gendell jeffrey l | - | - | -5.71M |
Vivo capital | - | - | -3.97M |
Sold Out
Holder | Change |
---|---|
Zurcher kantonalbank (zurich cantonalbank) | -19.00 |
Signaturefd | -22.00 |
Cwm | -99.00 |
First manhattan co. llc. | -100.00 |
Org partners | -129.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Sep 30, 2024 | 5 | -50.00% | 1,070,001 | -84.77% | 1 | 1.89% | - | -100.00% | 1 | - |
Jun 30, 2024 | 10 | -92.42% | 7,025,014 | -89.75% | 7 | 0.10% | 3 | -96.05% | 1 | -96.67% |
Mar 31, 2024 | 132 | 8.20% | 68,522,967 | 22.31% | 85 | 2.18% | 76 | 40.74% | 30 | 11.11% |
Dec 31, 2023 | 122 | 11.93% | 56,021,760 | 3.17% | 62 | 1.27% | 54 | 12.50% | 27 | 3.85% |
Sep 30, 2023 | 109 | -1.80% | 54,298,994 | 3.04% | 70 | 1.03% | 48 | -17.24% | 26 | 8.33% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Polar Capital Healthcare Opports Inc | 3.62M | 3.75% | - |
Vanguard Total Stock Mkt Idx Inv | 2.81M | 2.92% | - |
Janus Henderson Global Life Sciences D | 2.57M | 2.67% | -69.87K |
Janus Henderson Global Life Sciences | 2.54M | 2.64% | -131.86K |
iShares Russell 2000 ETF | 2.51M | 2.61% | -19.10K |
Janus Henderson Glb Life Scn I2 USD | 2.03M | 2.11% | 24.91K |
Janus Global Life Science AUSD | 2.03M | 2.11% | 39.47K |
Polar Capital Biotech S Inc | 1.50M | 1.56% | - |
Janus Henderson Venture D | 1.48M | 1.54% | 316.03K |
Janus Henderson US Small Cap Growth MA | 1.48M | 1.54% | 1.48M |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jan 21, 2025 | Palczuk Linda | - | Buy | $39.64K |
Jan 13, 2025 | Thornton Peter J. | - | Buy | $80.45K |
Jan 13, 2025 | Ende Eric J | - | Buy | $235.22K |
Dec 13, 2024 | MCHUGH THOMAS S | Chief Financial Officer | Buy | $24.02K |
Dec 11, 2024 | MCHUGH THOMAS S | Chief Financial Officer | Buy | $52.43K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | 3 | - |
2024 Q4 | 7 | - |
2024 Q3 | - | - |
2024 Q2 | - | - |
2024 Q1 | 1 | - |
AVDL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools